Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002836 · ClinicalTrials.gov registry record · Phase 3
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT00002836: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00002836 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 184 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002836, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus filgrastim with filgrastim alone in treating women undergoing peripheral stem cell transplantation for stage II, stage III, or metastatic breast cancer.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Carmustine
- DRUG Cyclophosphamide (CTX)
- BIOLOGICAL Filgrastim (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 1995-09-26 |
| Est. Completion | 2006-03-09 |
| Phase | Phase 3 |
What the finished NCT00002836 record still lists
NCT00002836 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00002836 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002836 about?
NCT00002836 is a clinical study titled "Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00002836?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 1995-09-26. Estimated completion is 2006-03-09.
What interventions are being tested in trial NCT00002836?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Carmustine (DRUG), Cyclophosphamide (CTX) (DRUG), Filgrastim (G-CSF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002836?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002836's enrollment target sits among peer trials
184 1418th of 2000 higher than 581 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI